ALLMedicine™ Alagille Syndrome Center

Sep 10th, 2021 - Odevixibat (Bylvay™) is a small molecule inhibitor of the ileal bile acid transporter being developed by Albireo Pharma, Inc. for the treatment of various cholestatic diseases, including progressive familial intrahepatic cholestasis (PFIC). In Jul...

Aug 7th, 2021 - To assess the performance of a non-invasive screening test for a panel of dominant disorders with a combined population incidence of 1 in 600. The panel included 30 genes covering 25 disorders including Noonan spectrum disorders (NSDs), skeletal d...

Jul 3rd, 2021 - Alagille syndrome (ALGS) is an autosomal dominant disorder caused by pathogenic variants in JAG1 or NOTCH2, which encode fundamental components of the Notch signaling pathway. Clinical features span multiple organ systems including hepatic, cardia...

Jul 3rd, 2021 - The Alagille syndrome (AGLS) is a rare condition, with few studies reported in the literature, especially in the field of dentistry. It consists of a disease involving many systemic problems and specific facial features. The liver and heart are th...

Jun 30th, 2021 - The purpose of this study was to characterize the phenotypic spectrum of ophthalmic findings in patients with Alagille syndrome. We conducted a retrospective, observational, multicenter, study on 46 eyes of 23 subjects with Alagille syndrome. We r...

Oct 11th, 2017 - WASHINGTON, DC — Advances in the treatment of nonalcoholic steatohepatitis (NASH) — including results from a phase 2 trial of a liver-targeted selective inhibitor of acetyl-CoA carboxylase — will be in the spotlight here at The Liver Meeting 2017:...

Oct 11th, 2017 - WASHINGTON, DC — Advances in the treatment of nonalcoholic steatohepatitis (NASH) — including results from a phase 2 trial of a liver-targeted selective inhibitor of acetyl-CoA carboxylase — will be in the spotlight here at The Liver Meeting 2017:...

Apr 8th, 2016 - Intrahepatic Cholestasis Neonatal cholestasis results from a heterogeneous group of intrahepatic disorders caused by mutations in several genes.[28] Recent advances in the understanding of the molecular basis of genetic cholestatic syndromes, such...

Oct 5th, 2005 - Discussion Congenital biliary atresia manifests in the early neonatal period as jaundice. The disease, which represents congenital fibrosis of the extrahepatic biliary system, is divided into multiple types, depending on the location of the atresi...